| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | vedolizumab (Entyvio®) |
| Formulation | 108 mg solution for injection |
| Reference number | 3335 |
| Indication | Treatment of inflammatory bowel disease including Crohn's disease and ulcerative colitis |
| Company | Takeda UK Ltd |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 11/03/2020 |